24/7 Market News Snapshot 11 June, 2025 – Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS)

June 11, 2025

DENVER, Colo., 11 June, 2025 (www.247marketnews.com) – (Nasdaq:INTS) are discussed in this article.
Intensity Therapeutics, Inc. (Nasdaq:INTS), a late-stage clinical biotechnology company focused on developing innovative intratumoral cancer therapies, today announced plans for a public offering of its common stock aimed at supporting its groundbreaking cancer treatment initiatives. The move comes as the company’s stock opened at $0.493, currently trading at $0.466 after experiencing a substantial decline of approximately 7.36% following a previous session close of $0.503. This downturn reflects a weakened buying momentum amid cautious market sentiment, influenced by both broader market conditions and company-specific developments.

The net proceeds from the upcoming offering are intended to enhance patient enrollment in the pivotal INVINCIBLE-4 Study and to further treatment protocols for participants in the ongoing INVINCIBLE-3 Study. Additionally, these funds will provide essential working capital to support general corporate needs. This strategic funding underscores the Company’s goals to improve cancer treatment protocols and transform the management of challenging malignancies.

The offering will proceed under a shelf registration statement filed with the U.S. Securities and Exchange Commission, with terms outlined in a prospectus supplement, accessible on the SEC’s website as well as via the appointed book-running manager for the offering.

Intensity Therapeutics is committed to pioneering cancer therapy, utilizing engineered drug formulations designed to specifically target tumors and activate robust immune responses. The Company has reported successes in completed clinical studies, having enrolled over 200 patients, as it continues to evaluate potential treatments for patients unresponsive to conventional therapies. As it progresses through these trials, Intensity remains focused on its mission to expand access to its innovative therapies and enhance patient care in the ongoing battle against cancer.

Related news for (INTS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.